Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group

Jolyon P. Mitchell; Ariel Berlinski; Sebastian Canisius; David Cipolla; Myrna B. Dolovich; Igor Gonda; Guenther Hochhaus; Nani Kadrichu; Svetlana Lyapustina; Heidi M. Mansour; Chantal Darquenne; Andy R. Clark; Michael Newhouse; Stephan Ehrmann; Robert Humphries; Homer Boushey

doi:10.1089/jamp.2020.1622

Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group

Jolyon P. Mitchell
, Ariel Berlinski
, Sebastian Canisius
, David Cipolla
, Myrna B. Dolovich
, Igor Gonda
, Guenther Hochhaus
, Nani Kadrichu
, Svetlana Lyapustina
, Heidi M. Mansour
, Chantal Darquenne
, Andy R. Clark
, Michael Newhouse
, Stephan Ehrmann
, Robert Humphries
, Homer Boushey

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	235-238
Number of pages	4
Journal	Journal of Aerosol Medicine and Pulmonary Drug Delivery
Volume	33
Issue number	4
DOIs	https://doi.org/10.1089/jamp.2020.1622
State	Published - Aug 1 2020

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Pharmaceutical Science
Pharmacology (medical)

Access to Document

10.1089/jamp.2020.1622

Cite this

Mitchell, J. P., Berlinski, A., Canisius, S., Cipolla, D., Dolovich, M. B., Gonda, I., Hochhaus, G., Kadrichu, N., Lyapustina, S., Mansour, H. M., Darquenne, C., Clark, A. R., Newhouse, M., Ehrmann, S., Humphries, R., & Boushey, H. (2020). Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 33(4), 235-238. https://doi.org/10.1089/jamp.2020.1622

Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. / Mitchell, Jolyon P.; Berlinski, Ariel; Canisius, Sebastian et al.
In: Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 33, No. 4, 01.08.2020, p. 235-238.

Research output: Contribution to journal › Letter › peer-review

Mitchell, JP, Berlinski, A, Canisius, S, Cipolla, D, Dolovich, MB, Gonda, I, Hochhaus, G, Kadrichu, N, Lyapustina, S, Mansour, HM, Darquenne, C, Clark, AR, Newhouse, M, Ehrmann, S, Humphries, R & Boushey, H 2020, 'Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group', Journal of Aerosol Medicine and Pulmonary Drug Delivery, vol. 33, no. 4, pp. 235-238. https://doi.org/10.1089/jamp.2020.1622

Mitchell JP, Berlinski A, Canisius S, Cipolla D, Dolovich MB, Gonda I et al. Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2020 Aug 1;33(4):235-238. doi: 10.1089/jamp.2020.1622

Mitchell, Jolyon P. ; Berlinski, Ariel ; Canisius, Sebastian et al. / Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19 : Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. In: Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2020 ; Vol. 33, No. 4. pp. 235-238.

@article{4198cceb0fb740bab3372ba27aa10a61,

title = "Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group",

author = "Mitchell, \{Jolyon P.\} and Ariel Berlinski and Sebastian Canisius and David Cipolla and Dolovich, \{Myrna B.\} and Igor Gonda and Guenther Hochhaus and Nani Kadrichu and Svetlana Lyapustina and Mansour, \{Heidi M.\} and Chantal Darquenne and Clark, \{Andy R.\} and Michael Newhouse and Stephan Ehrmann and Robert Humphries and Homer Boushey",

note = "Funding Information: J.P.M., S.C., M.B.D., G.H., S.L., H.M.M., C.D., and B.H. register no conflict of interest. D.C. is an employee of Insmed Incorporated. I.G. consults for companies developing potential inhaled prophylaxes and treatments for COVID-19 infections. A.C. is an employee of Aerogen Pharma Corporation, N.K. and M.N. consult for companies developing inhaled pharmaceutical products. A.B. served as principal investigator in studies sponsored by AbbVie, Allergan, Anthera, DCI, Cempra, Cystic Fibrosis Foundation, National Institute of Health, No-vartis, Therapeutic Development Network, Trudell Medical International, Vertex, and Vivus and he serves as science advisor to the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). S.E. received unrestricted research grants, travel fee reimbursements, and speaker fees from Fisher and Paykel health care, consulting fees from La Diffusion Technique Franc¸aise, consulting fees and unrestricted research grants from Aerogen Ltd., research support for Penn Century, and unrestricted research grant from Hamilton Medical. H.B. is a medical consultant including for Pulmoquine, a company investigating an inhaled therapy for prevention and treatment of COVID-19.",

year = "2020",

month = aug,

day = "1",

doi = "10.1089/jamp.2020.1622",

language = "English (US)",

volume = "33",

pages = "235--238",

journal = "Journal of Aerosol Medicine and Pulmonary Drug Delivery",

issn = "1941-2711",

publisher = "Mary Ann Liebert Inc.",

number = "4",

}

TY - JOUR

T1 - Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19

T2 - Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group

AU - Mitchell, Jolyon P.

AU - Berlinski, Ariel

AU - Canisius, Sebastian

AU - Cipolla, David

AU - Dolovich, Myrna B.

AU - Gonda, Igor

AU - Hochhaus, Guenther

AU - Kadrichu, Nani

AU - Lyapustina, Svetlana

AU - Mansour, Heidi M.

AU - Darquenne, Chantal

AU - Clark, Andy R.

AU - Newhouse, Michael

AU - Ehrmann, Stephan

AU - Humphries, Robert

AU - Boushey, Homer

N1 - Funding Information: J.P.M., S.C., M.B.D., G.H., S.L., H.M.M., C.D., and B.H. register no conflict of interest. D.C. is an employee of Insmed Incorporated. I.G. consults for companies developing potential inhaled prophylaxes and treatments for COVID-19 infections. A.C. is an employee of Aerogen Pharma Corporation, N.K. and M.N. consult for companies developing inhaled pharmaceutical products. A.B. served as principal investigator in studies sponsored by AbbVie, Allergan, Anthera, DCI, Cempra, Cystic Fibrosis Foundation, National Institute of Health, No-vartis, Therapeutic Development Network, Trudell Medical International, Vertex, and Vivus and he serves as science advisor to the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). S.E. received unrestricted research grants, travel fee reimbursements, and speaker fees from Fisher and Paykel health care, consulting fees from La Diffusion Technique Franc¸aise, consulting fees and unrestricted research grants from Aerogen Ltd., research support for Penn Century, and unrestricted research grant from Hamilton Medical. H.B. is a medical consultant including for Pulmoquine, a company investigating an inhaled therapy for prevention and treatment of COVID-19.

PY - 2020/8/1

Y1 - 2020/8/1

UR - https://www.scopus.com/pages/publications/85088881106

UR - https://www.scopus.com/pages/publications/85088881106#tab=citedBy

U2 - 10.1089/jamp.2020.1622

DO - 10.1089/jamp.2020.1622

M3 - Letter

C2 - 32589076

SN - 1941-2711

VL - 33

SP - 235

EP - 238

JO - Journal of Aerosol Medicine and Pulmonary Drug Delivery

JF - Journal of Aerosol Medicine and Pulmonary Drug Delivery

IS - 4

ER -

Urgent Appeal from International Society for Aerosols in Medicine (ISAM) during COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this